Scala Biodesign

Scala Biodesign

Private
Tel AvivAI, Data & Cloud Infrastructurehttps://www.scala-bio.com/

Last Round

Series A

Mar 31, 2026

Total Funding Raised

$21.5M

Momentum Score

50 /100

Company Overview

Scala Biodesign is a biotechnology company that provides a computational platform using physics-based modeling, AI, and biological data analysis to engineer and design proteins for the pharmaceutical, chemical, and food industries.

Sector

AI, Data & Cloud Infrastructure

Verticals

Biotechnology, ML Platforms, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Subscription SaaS, Revenue Share

AI Layer

Infrastructure

Keywords

computational protein designprotein design platformprotein engineeringAI protein designgenerative biologyAI drug discoveryin silico designphysics-based modelingdrug discoveryenzyme designantibody engineeringprotein stabilitytherapeutic protein designatomistic modelingvaccine designbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Scala Biodesign Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Scala Biodesign Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series AMar 31, 2026
SeedSep 11, 2023

Key People

Founding team and executive leadership

Adi Goldenzweig

Co-Founder CTO

Founding Team

Ravit Netzer

Co-founder And CEO

Founding Team

Scala Biodesign Investors

Notable investors and investment history

InvestorRounds
Deep InsightSeries A
Israel Innovation AuthoritySeries A
Grove VenturesSeries A
TLV PartnersSeries A, Seed
Intel IgniteSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Core technology developed at Weizmann Institute of Science.

  • Mar 31, 2026

    Developing ScalaOS, a platform for creating protein-based products.

Scala Biodesign Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Scala Biodesign Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Scala Biodesign's valuation, stock price, and market status.

Firmographic Details

HeadquartersTel Aviv
Employee Range25
Year Founded2022
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.